BFRI BFRI
Company Profile ↓Company Overview
BFRI (BFRI) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 17.2% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $41.70M (+11.7% YoY); net profit $-10.54M.
- Trailing 12 Months Year-on-year growth — revenue +11.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 17.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 17.21% |
| 1 Year: | 11.75% |
Stock Price Performance
| 1 Year: | +23.38% |
| 6 Months: | +44.35% |
| 3 Months: | +7.83% |
| 1 Month: | +6.90% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)64.22 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 17.2% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.25M | 4.74M | 5.86M | 4.33M | 9.75M | 4.46M | 4.32M | 8.73M | 5.85M | 8.90M | 7.91M | 7.84M | 9.01M | 8.59M | 9.03M | 6.99M | 10.08M |
| Operating Income | -2.34M | -3.53M | -3.69M | -16.11M | -3.11M | -6.21M | -3.64M | -5.49M | -8.70M | -4.62M | -5.47M | -5.07M | -4.96M | -4.55M | -5.08M | -6.28M | -4.32M |
| Net Income | -2.98M | -3.53M | -3.66M | -16.01M | 5.56M | -850.00K | -2.57M | -7.48M | -9.84M | -6.34M | -10.44M | -257.00K | -5.67M | -4.20M | -5.32M | -6.65M | -4.75M |
| Diluted EPS | - | -0.44 | -0.46 | -2.00 | 0.32 | -0.90 | -2.26 | -5.60 | -7.23 | -4.64 | -2.88 | -0.05 | -0.98 | -0.47 | -0.57 | -0.62 | -0.41 |
| R&D Expense | - | - | - | - | - | - | - | - | 11.00K | 33.00K | 17.00K | 621.00K | 669.00K | 1.21M | 870.00K | 854.00K | 900.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 18.85M | 24.10M | 28.67M | 34.07M | 37.32M | 41.70M |
| Operating Income | -9.61M | -25.20M | -18.58M | -22.68M | -17.21M | -11.35M |
| Net Income | -10.99M | -37.71M | -640.00K | -20.13M | -17.76M | -10.54M |
| Diluted EPS | - | - | -0.61 | -13.02 | -3.22 | -1.04 |
| R&D Expense | - | - | - | 77.00K | 2.09M | 3.72M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 24.14M | 53.22M | 50.88M | 27.93M | 22.10M | 28.56M |
| Total Equity | -30.18M | 5.83M | 11.34M | 23.88M | 4.79M | 4.43M | 10.48M |
| Cash & Equivalents | - | 8.08M | 24.55M | 17.21M | 1.34M | 5.91M | 6.39M |
| Total Liabilities | - | 18.31M | 41.88M | 27.01M | 23.14M | 17.67M | 18.08M |
| Current Liabilities | - | 4.42M | 13.84M | 20.89M | 18.09M | 12.02M | 11.89M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -12.37M | -26.71M | -16.20M | -24.89M | -10.27M | -13.36M |
| Investing Cash Flow | - | -11.00K | -5.16M | 619.00K | -3.00K | 3.00M |
| Financing Cash Flow | 13.19M | 43.19M | 14.02M | 8.41M | 14.84M | 10.85M |
| Capital Expenditure | - | - | -38.00K | -5.00K | -10.00K | -2.00K |
| Free Cash Flow | - | - | -16.24M | -24.90M | -10.28M | -13.36M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -51.0% | -104.6% | -64.8% | -66.6% | -46.1% | -27.2% |
| Net Margin % | -58.3% | -156.5% | -2.2% | -59.1% | -47.6% | -25.3% |
| ROE % | -188.5% | -332.6% | -2.7% | -420.0% | -400.6% | -100.5% |
| ROCE % | -48.7% | -64.0% | -62.0% | -230.4% | -170.7% | -68.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BFRI
Biofrontera (BFRI) Q1 2026 Earnings Transcript
All risks and uncertainties are detailed in and are qualified by the cautionary statements contained in Biofrontera's press releases and SEC filings, including the company's quarterly report on Form 10-Q for the quarter ended March 31, 2026…
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will particip…
Biofrontera Inc (BFRI) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...
Biofrontera Inc (BFRI) reports a 17% revenue increase and significant margin expansion, while navigating increased expenses and regulatory uncertainties.
Biofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimates
Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of -127.78% and +6.15%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
Woburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported fin…
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026
WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it …
BFRI — Frequently Asked Questions
What is the current share price of BFRI?
As of 2026-08-05 17:25 PDT, BFRI trades at $1.24 on NASDAQ/NYSE. Its 52-week range is $0.57 to $1.24.
What is the P/E ratio of BFRI?
BFRI trades at a trailing price-to-earnings (P/E) ratio of -1.19.
What is the return on equity (ROE) of BFRI?
BFRI has a return on equity (ROE) of -100.53%. Its return on capital employed (ROCE) is -68.08%.
Is BFRI a good stock to buy?
This page provides a data-driven analysis of BFRI, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.